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Abstract
Background: Although liver function tests (LFTs) are routinely measured in primary care, raised levels in patients with no
obvious liver disease may trigger a range of subsequent expensive and unnecessary management plans. The aim of this
study was to develop and validate a prediction model to guide decision-making by general practitioners, which estimates
risk of one year all-cause mortality in patients with no obvious liver disease.
Methods: In this population-based historical cohort study, biochemistry data from patients in Tayside, Scotland, with LFTs
performed in primary care were record-linked to secondary care and prescription databases to ascertain baseline
characteristics, and to mortality data. Using this derivation cohort a survival model was developed to predict mortality. The
model was assessed for calibration, discrimination (using the C-statistic) and performance, and validated using a separate
cohort of Scottish primary care practices.
Results: From the derivation cohort (n = 95 977), 2.7% died within one year. Predictors of mortality included: age; male
gender; social deprivation; history of cancer, renal disease, stroke, ischaemic heart disease or respiratory disease; statin use;
and LFTs (albumin, transaminase, alkaline phosphatase, bilirubin, and gamma-glutamyltransferase). The C-statistic for the
final model was 0.82 (95% CI 0.80–0.84), and was similar in the validation cohort (n = 11 653) 0.86 (0.79–0.90). As an example
of performance, for a 10% predicted probability cut-off, sensitivity = 52.8%, specificity = 94.0%, PPV= 21.0%, NPV = 98.5%.
For the model without LFTs the respective values were 43.8%, 92.8%, 15.6%, 98.1%.
Conclusions: The Algorithm for Liver Function Investigations (ALFI) is the first model to successfully estimate the probability
of all-cause mortality in patients with no apparent liver disease having LFTs in primary care. While LFTs added to the model’s
discrimination and sensitivity, the clinical utility of ALFI remains to be established since LFTs did not improve an already
high NPV for short term mortality and only modestly improved a very low PPV.
Citation: McLernon DJ, Dillon JF, Sullivan FM, Roderick P, Rosenberg WM, et al. (2012) The Utility of Liver Function Tests for Mortality Prediction within One Year
in Primary Care Using the Algorithm for Liver Function Investigations (ALFI). PLoS ONE 7(12): e50965. doi:10.1371/journal.pone.0050965
Editor: Mercedes Susan Mandell, University of Colorado, United States of America
Received May 3, 2012; Accepted October 29, 2012; Published December 14, 2012
Copyright:  2012 McLernon et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Health Service Research & Development Programme Health Technology Assessment Programme (project
number 03/38/02) and the Backett Weir Russell Career Development Fellowship. Department of Health Disclaimer: The views and opinions expressed therein are
those of the authors and do not necessarily reflect those of the Department of Health. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: DJM (while employed by the University of Dundee), PTD, JFD,
and FMS declare financial support to their institutions for the submitted work from the UK National Health Service Research & Development Programme Health
Technology Assessment Programme. DJM declares financial support to his institution for the submitted work from the Backett Weir Russell Career Development
Fellowship. SR received reimbursement of travel costs to attend study meetings from the UK National Health Service Research & Development Programme Health
Technology Assessment Programme grant. PR and WMR have no competing interests to declare.
* E-mail: d.mclernon@abdn.ac.uk
Introduction
Liver function tests (LFTs) are frequently requested and often
difficult to interpret in primary care. The results obtained may
lead to further invasive and expensive investigations which may be
unnecessary. There are a wide variety of reasons for testing liver
function including: routine health checks; investigation of non-
specific symptoms such as fatigue or nausea; presence of risk
factors for liver diseases such as alcohol misuse and/or clinical
diagnosis of liver disease; suspected gallbladder or pancreatic
problems, and monitoring of drugs such as statins.
Despite increasing numbers of LFTs being performed in the
UK [1,2] some patients continue to present with potentially fatal
severe liver disease, which may have been preventable through
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earlier diagnosis. In patients with raised LFTs but no obvious liver
disease, there may be uncertainty about subsequent management.
Abnormal LFTs may also signify other serious diseases that might
benefit from earlier diagnosis and or intervention (therapeutic and
palliative), such as metastatic malignancy, congestive heart failure,
and systemic inflammatory conditions [3–7]. All of these potential
diagnoses add to the uncertainty surrounding management
strategies leading to variation in clinical practice with probable
over-investigation of some patients and under-investigation of
others. In some, early detection and intervention could result in
reduced morbidity and mortality and/or better quality of life [8].
Furthermore, patients may have raised LFTs and be asymptom-
atic which could indicate disease such as non-alcoholic fatty liver
disease [2], or they may be healthy and the abnormal result is a
false positive. In the latter case the initial abnormality may then
lead to unnecessary investigations and secondary care referral
causing anxiety and increased health service costs [9]. A decision
support tool incorporating a clinical prediction rule could facilitate
the management of these patients in primary care.
Clinical prediction models enable accurate probabilities of
specific outcomes to be calculated based on characteristics related
to the patient, disease or treatment and are a key component of
stratified medicine. They are a prognostic strategy often used in
primary care [10] of which the Framingham risk score for
cardiovascular disease is just one of many [11–13]. Before
conversion into a user-friendly web-based tool, they must be
assessed for predictive ability and externally validated [14,15]. A
model that could predict short-term mortality would enable the
GP to identify those patients with a very poor prognosis who need
immediate referral to secondary care. It would also identify
patients with good prognosis who do not require further
investigation.
This population-based historical cohort study followed-up
patients living in Tayside, Scotland with no clinically recognised
liver disease who initially had LFTs undertaken in primary care
[16]. The aim was to derive, assess, and externally validate a
predictive model that would estimate the risk of mortality from any
cause in liver function tested patients in primary care over a one
year period, for subsequent use by general practitioners to aid their
decision making.
Methods
Separate populations were used to develop the prognostic model
(derivation cohort) and then externally validate it (validation
cohort) [15].
Derivation cohort
The study population was derived from a population laboratory
database which contains all electronically available LFT results
from patients within Tayside, Scotland, UK during the fifteen year
period from January 1989 to December 2003. Tayside is a mixed
urban/rural region characteristic of the UK with a population of
approximately 410000 [17]. LFTs included bilirubin, albumin,
alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT),
alanine transaminase, and aspartate aminotransferase. Since many
laboratories only measure either alanine transaminase or aspartate
aminotransferase these two similar tests were combined as one test
and are referred to as transaminases in the rest of this paper.
Patients aged 16 and above with no obvious or reported clinical
signs of liver disease upon presentation to a general practitioner,
with at least 2 different LFTs requested from the index
appointment, between 1989 and 2003 were eligible for inclusion.
The following exclusion criteria ensured that the study population
of patients had no clinically recognised liver disease at presentation
in primary care:
N Patients whose bilirubin result was greater than 35 mmol/L in
their initial batch of tests, i.e. clinically jaundiced.
N Patients who had a complication of severe liver disease within
6 weeks of their first LFTs (identified from the ELDIT
database detailed in Figure 1). These included ascites,
encephalopathy, varices, and portal hypertension.
N Patients with a history of liver disease before the study period
(identified from the ELDIT database).
Databases
In Tayside, all individuals registered with a general practitioner
have a unique identifier, the Community Health Index (CHI) [18].
The Health Informatics Centre, University of Dundee, securely
hold the CHI files for Tayside. The CHI files contain the CHI
number and the patient’s name, address and date of birth. The
CHI files are used for all health encounters in Tayside and enable
record-linkage of both primary and secondary care data. For
research studies the datasets listed in Figure 1 were anonymised
according to the Standard Operating Procedures of the Health
Informatics Centre, University of Dundee [17]. Using the Tayside
biochemistry database as the base population, all of the databases
listed in Figure 1 were record-linked to it using an anonymous
identifier linked to the CHI number.
Ethics statement
Ethical approval was obtained from the Tayside Committee for
Medical Research Ethics in February 2005. Written informed
consent from patients was waived by the Tayside Committee for
Medical Research Ethics because the databases were anonymised
so that no patient identifiable information was accessible. The
databases relevant to this study (see Figure 1) covered the entire
study period and were used in accordance with procedures
Figure 1. Databases record-linked to create the Tayside
derivation cohort.
doi:10.1371/journal.pone.0050965.g001
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approved under the Caldicott Guardian and the Data Protection
Act UK (1998) in line with the European directive of 1995.
Baseline characteristics
The databases (Figure 1) identified baseline characteristics and
outcomes of the population. As well as the five LFTs, baseline
characteristics included age, gender, deprivation [19], comorbid-
ities (from SMR01) during the period 1980 to study start (including
cancer, diabetes, ischaemic heart disease (IHD), stroke, renal
disease, respiratory disease, and biliary disease), diagnosed alcohol
and drug dependency (from SMR01 and SMR04), methadone
use, pregnancy, and use of statins, non-steroidal anti-inflammatory
drugs (NSAIDs) or antibiotic use in the three months before LFTs.
Since bilirubin was truncated to ,36 mmol/L, it was categorised
into normal and mildly raised, where normal is ,18 mmol/L for
males and ,16 mmol/L for females.
Outcomes
The primary outcome was all-cause mortality during the follow-
up year. Patients who died were identified from the Scottish
National Death Registry. Underlying causes of death were
tabulated for the derivation population and categorised using
versions 9 and 10 of the International Classification of Diseases.
Statistical analysis
Parametric survival regression models were fitted to investigate
the effect of baseline characteristics on time to all-cause mortality.
The starting point was taken as the date of the initial LFT test and
the endpoint was one year later, 31st December 2003, date of
emigration, or death, whichever was earlier. All patients whose
endpoint was not death were censored.
The continuous baseline characteristics of age, albumin, ALP,
GGT, and transaminase were assessed for their functional form by
plotting them against the Martingale residuals and appropriate
transformations were carried out, where necessary. The Weibull
accelerated failure time model was used for model building, which
was conducted in a manual stepwise manner. A multiple
imputation procedure was conducted to impute missing baseline
data [25]. Every model during the model building procedure was
fitted to 30 imputed datasets arising from the multiple imputation
procedure. The parameter estimates and covariances from each
imputed dataset were combined to produce inferential results
using PROC MIANALYZE in SAS. For each model, the Akaike’s
information criterion (AIC) statistic was calculated and the average
AIC was taken over all 30 imputed datasets. The model with the
smallest AIC was considered the optimal model. Two-way
covariate interactions were also investigated. The final models
were then fitted using different parametric distributions including
the generalised gamma, log-logistic, log-normal, and exponential
distributions to find the best fit. All patients with complete data
were analysed separately as a sensitivity analysis.
The final model was assessed for predictive ability to examine its
ability at discriminating high from low risk using the C-statistic
[14]. The model’s predicted probabilities were assessed for
accuracy using calibration plots and testing the calibration slope
[26] (more detailed information on multiple imputation and
calibration is presented in Appendix S1). The integrated
discrimination index (IDI) was used to measure the improvement
in the model for each individual covariate [27]. The IDI is the
difference between the proportion of variance explained by the full
model and the model without the covariate of interest. The
sensitivity, specificity, positive predictive value (PPV), and negative
predictive value (NPV) were calculated for different risk cut-offs,
accounting for censoring [27].
External validation
The validation cohort contained all patients registered with 19
practices from across Scotland out with Tayside. The practices
were participating in the Practice Team Information project
operated by the Information Services Division of the National
Health Service National Services Scotland, and contributing data
to the Primary Care Clinical Informatics Unit, University of
Aberdeen [28,29]. The patient population within the Primary
Care Clinical Informatics Unit database is broadly representative
of the Scottish population, with respect to age, sex, and social
deprivation [29]. The validation cohort contained patients having
their initial LFTs measured in primary care between January 2004
and August 2008. All eligible patients had to have test results for
ALP, bilirubin, albumin, and transaminase. All baseline charac-
teristics and outcome data obtained for the derivation cohort were
also obtained for the validation cohort. No record-linkage to other
databases was needed since all of the information was contained in
the Primary Care Clinical Informatics Unit database. The same
exclusion criteria listed above was also applied to the validation
cohort.
The final model was fitted to the validation cohort using the
same parameter estimates derived from the study population. The
C-statistic was calculated and the calibration plot drawn as for the
study population to assess the performance of the model on the
external validation cohort. A further model was fitted to the
validation cohort using the same covariates as for the final model
and its C-statistic computed. The resulting parameter estimates
were compared to the final model’s parameter estimates using the
z-test to test for equality [30]. The calibration slope was tested and
the model recalibrated if required.
Analyses were performed using SAS (v9.2) (SAS Institute, Cary,
North Carolina).
Results
Baseline characteristics
After exclusions our derivation cohort contained 95977 patients
with incident initial LFTs taken in primary care and with no
obvious liver disease [1]. Only 719 (0.75%) patients had both ALT
and AST recorded. In these cases the ALT result was included in
the analysis for consistency since the majority of patients with ALT
or/and AST tested had ALT tested (87%). Table 1 shows the
baseline characteristics of the cohort. There were more females
(57.9%) than males (42.1%), and the median (interquartile range)
age was 54.6 (39.2–68.8) years. The most frequent previously
known baseline co-morbidity was IHD (5.6%), followed by cancer
(3.8%). 8.7% of patients were prescribed antibiotics during the
three months before their initial LFTs, whilst 3.3% were
prescribed statins.
Missing data
Only 8388 (8.7%) patients were tested for all five liver enzymes.
The percentage of complete data for each LFT was as follows:
ALP (99.2%), albumin (99.2%), bilirubin (93.6%), transaminases
(76.5%), and GGT (10.9%). There were more males with
complete data (i.e. having all five liver enzymes measured) than
females (54.6% versus 45.4%) (Appendix S2). The group with
complete data were also more deprived and contained more
alcohol dependent patients than the incomplete data group. A
multiple imputation procedure was performed to impute missing
or untested LFT results as detailed in appendix S1.
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All-cause mortality
A total of 2613 patients (2.7%) died of any cause during one
year follow-up. The commonest underlying cause of death was
cancer (39.3%) (Table 2). Of these, gastrointestinal (30.6%) and
lung cancers (29.7%) were the most frequent. Of those who died
from cancer, 77% had no history of cancer recorded at baseline.
Diseases of the circulatory system were the second commonest
cause of death (34.7%), and of these, IHD was the most frequent
(55.9%). Of those who died from IHD, 77% had no history of
IHD. Cause of death was missing for 90 patients (3.4%).
Prediction of all-cause mortality
The final model is presented in Table 3 where the baseline
characteristics are sorted in descending order of the IDI statistic. All
five LFTs were predictive of mortality with albumin the strongest,
followed closely by ALP. History of cancer had a strong effect on
mortality, and renal disease, stroke, IHD, and respiratory disease
were also highly associated with mortality. The model also indicated
that being male, increasing age and deprivation were associated with
increased risk of death within a year. Statins were significantly
associated with reduced risk of mortality. Age interacted with gender,
deprivation, cancer, ALP, and transaminase, and although these were
significant terms, the coefficients were small. History of diabetes,
NSAID use, antibiotic use, methadone use, alcohol dependency, and
drug dependency were not predictive of mortality. The IDI statistic
showed that patient age explained the greatest percentage of variance
in the model. This was followed by albumin and ALP result. Adding
the four LFTs to the model without any LFTs gave an IDI of 15%.
Predictive ability of derivation cohort model
The C-statistic for discriminatory ability of the prediction model for
risk of one year mortality was 0.82 (95% CI 0.80, 0.84). With LFTs
excluded the C-statistic was lower with a value of 0.79 (95% CI 0.76,
0.81) in the derivation cohort, and demonstrates that LFTs add some
discriminatory ability to the model. Figure 2 displays the observed
versus the predicted number of deaths by tenths of predicted
probability of mortality from the model. Although tenths 5 to 9 show
some visible evidence of over-prediction of mortality, the top tenth of
predicted mortality is similar to the observed mortality. The calibration
slope test showed no evidence of over-fitting (see Appendix S3). The
sensitivity, specificity, PPV and NPV for different cut-offs of predicted
risk of mortality are displayed in Table 4. For example, a cut-off greater
than or equal to 0.61% (the median predicted probability of mortality)
had a low PPV of 5.7% and high NPV of 99.8%.
For a model without LFTs the performance measures were
similar to the full model for the median cut-off (see Table 5). For
example, for a cut-off greater than or equal to 10%, the PPV
increased from 15.6% to 21.0% for the full model. The sensitivity,
Table 1. Baseline and historical characteristics of the derivation cohort (n = 95977) and the validation cohort (n = 11653).
Cohort n(%) or Median (IQR)
Baseline Characteristics Derivation Validation
Age (years ) 54.6 (39.2–68.8) 60.0 (47.0, 72.0)
Gender Male 40374 (42.1) 5271 (45.2)
Female 55603 (57.9) 6382 (54.8)
Carstairs category Affluent 47286 (49.3) 2753 (23.6)
Deprived 48691 (50.7) 8900 (76.4)
Comorbidity history Cancer1 3629 (3.8) 956 (8.2)
Diabetes 1386 (1.4) 1441 (12.4)
IHD 5370 (5.6) 2034 (17.5)
Renal disease 141 (0.2) 155 (1.3)
Respiratory disease 2636 (2.8) 883 (7.6)
Stroke 1471 (1.5) 583 (5.0)
Medication in previous 3 months Statins 3176 (3.3) 3178 (27.3)
NSAIDs 6698 (7.0) 1762 (15.1)
Antibiotics 8307 (8.7) 1962 (16.8)
Abusive substance Alcohol 2632 (2.7) 465 (4.0)
Drug 371 (0.4) 0 (0.0)
Methadone 377 (0.4) 10 (0.1)
Liver function tests Albumin (g/L) 44.0 (42.0–46.0) 44.0 (41.0, 46.0)
ALP (U/L) 76.0 (62.0–94.0) 75.0 (62.0, 92.0)
Transaminase (U/L) 18.0 (14.0–26.0) 21.0 (16.0, 30.0)
GGT (U/L) 26.0 (17.0–47.0) 27.0 (18.0, 45.0)
Normal Bilirubin2 81111 (91.0) 10587 (90.8)
Mildly raised Bilirubin2 8058 (9.0) 1066 (9.2)
1Not including biliary cancer or hepatocellular cancer;
2Normal bilirubin is defined as 0–15 mmol/L for females and 0–17 mmol/L for males; Mildly raised bilirubin is defined as 16–35 mmol/L for females and 18–35 mmol/L for
males.
IQR interquartile range; IHD ischaemic heart disease; NSAID non-steroidal anti-inflammatory; ALP alkaline phosphatase; GGT gamma-glutamyltransferase.
doi:10.1371/journal.pone.0050965.t001
Predicting Mortality following Liver Function Tests
PLOS ONE | www.plosone.org 4 December 2012 | Volume 7 | Issue 12 | e50965
specificity and NPV increased from 43.8% to 52.3%, from 92.8%
to 94.0%, and from 98.1% to 98.5% respectively.
External validation
The external cohort contained 11653 patients (Table 1). The
proportion of males and females were reasonably similar to the
population used to develop the model (45.2% versus 42.1% males).
The median age was five years older and there were a greater
proportion of deprived patients (76.4% versus 50.7%). There were
also consistently more patients with co-morbidities and medica-
tions. However, the median LFTs were similar between the two
cohorts. GGT was missing for 4178 (35.9%) patients and so were
imputed in a similar manner as for the main study population. A
total of 325 patients (2.8%) died within one year.
Table 2. Causes of mortality within one year of liver function tests.
Underlying cause of death n %
Neoplasms: 1027 39.3
Malignant neoplasm of digestive organs and peritoneum 314 12.0
Malignant neoplasm of respiratory and intrathoracic organs 305 11.7
Malignant neoplasm of other and unspecified sites 138 5.3
Malignant neoplasm of genitourinary organs 125 4.8
Malignant neoplasm of bone, connective tissue, skin and breast 72 2.8
Malignant neoplasm of lymphatic and hematopoietic tissue 49 1.9
Malignant neoplasm of lip, oral cavity and pharynx 13 0.5
Neoplasm of unspecified nature 6 0.2
Neoplasm of uncertain behaviour 2 0.1
Benign neoplasm 2 0.1
Malignant neoplasm of independent (primary) multiple sites 1 0.0
Diseases of the circulatory system: 907 34.7
Ischaemic heart disease 507 19.4
Cerebrovascular disease 208 8.0
Other forms of heart disease 94 3.6
Diseases of arteries, arterioles, and capillaries 36 1.4
Diseases of pulmonary circulation 26 1.0
Hypertensive disease 15 0.6
Diseases of veins and lymphatics, and other diseases of circulatory system 13 0.5
Chronic rheumatic heart disease 8 0.3
Diseases of the respiratory system: 258 9.9
Pneumonia and influenza 119 4.6
Chronic obstructive pulmonary disease and allied conditions 103 3.9
Other diseases of respiratory system 26 1.0
Pneumoconioses and other lung diseases due to external agents 9 0.3
Acute respiratory infections 1 0.0
Diseases of the digestive system 62 2.4
Injury and poisoning 59 2.3
Mental disorders 57 2.2
Diseases of the nervous system and sense organs 45 1.7
Diseases of the genitourinary system 39 1.5
Endocrine, nutritional and metabolic diseases, and immunity disorders 23 0.9
Diseases of the musculoskeletal system and connective tissue 14 0.5
Certain infectious and parasitic diseases 12 0.5
Diseases of blood and blood forming organs 8 0.3
Symptoms, signs and ill-defined conditions 8 0.3
Diseases of the skin and subcutaneous tissue 3 0.1
Congenital malformations, deformations and chromosomal abnormalities 1 0.0
Missing 90 3.4
Total 2613 100.0
Note: Causes of death in italics are subsets of those in normal font.
doi:10.1371/journal.pone.0050965.t002
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The C-statistic for the final model applied to the external cohort
was 0.86 (95% CI 0.79 to 0.90). The calibration slope test was
borderline significant meaning that the model required a small
amount of recalibrating which is usual in external validation (more
detail in Appendix S4).
Survival curves for specific groups and cases
Figure 3 presents the survival curves for males (Figure 3a) and
females (Figure 3b) with different histories of cancer and stroke
during the first year of follow-up. Although the curves are quite
similar for males and females, males had lower survival
probabilities, especially those with a history of stroke. Figure 4
shows the probability of survival during the year for the average
risk patient, a specific moderate-high risk case, and a specific very
high risk case (the characteristics of these latter two patients are as
described in the legend of Figure 4). The formula for calculating
mortality risk is presented in Appendix S5.
Discussion
We have developed and validated a model, the Algorithm for
Liver Function Investigations (ALFI), that can predict mortality
within one-year following liver function testing in primary care.
ALFI performs better at lower cut-offs of predicted probabilities.
The NPV and specificity measures were excellent but decreased
little when LFTs were removed from the model (for NPV this
reflects the low overall risk of mortality). However, whilst LFTs did
improve sensitivity and moderately improved an already low PPV,
the clinical utility needs to be established, e.g. through the use of a
Table 3. Parameter estimates of the final generalised gamma model predicting risk of all-cause mortality within 1 year of initial
liver function tests.
Parameter Coefficient (95% CI) P-value IDI, %
Intercept 15.158 (12.414 to 17.902) ,0.001
Age at baseline 20.127 (20.163 to 20.091) ,0.001 8.43a
Albumin 0.194 (0.181 to 0.207) ,0.001 4.66
Log (ALP) 22.179 (22.767 to 21.592) ,0.001 1.24a
Cancer (yes v no) 24.538 (25.393 to 23.683) ,0.001 0.42a
Gender (Male v Female) 21.184 (21.734 to 20.634) ,0.001 0.33a
Log (transaminase) 1.323 (0.755 to 1.891) ,0.001 0.26a
Log (GGT) 20.453 (20.660 to 20.246) ,0.001 0.17
Stroke (yes v no) 20.587 (20.800 to 20.375) ,0.001 0.13
Respiratory disease (yes v no) 20.605 (20.794 to 20.417) ,0.001 0.11
Bilirubin (mildly raised v normal) 20.403 (20.553 to 20.253) ,0.001 0.11
Renal disease (yes v no) 20.969 (21.520 to 20.418) ,0.001 0.09
Statins (yes v no) 0.617 (0.320 to 0.913) ,0.001 0.07
Deprived (yes v no) 20.999 (21.535 to 20.462) ,0.001 0.07a
IHD (yes v no) 20.259 (20.409 to 20.110) ,0.001 0.05
Age at baseline X Cancer 0.050 (0.038 to 0.061) ,0.001
Age at baseline X Log (ALP) 0.017 (0.009 to 0.025) ,0.001
Age at baseline X Deprived 0.011 (0.004 to 0.018) 0.002
Age at baseline X Log (transaminase) 20.010 (20.017 to 20.003) 0.006
Gender X Age at baseline 0.010 (0.003 to 0.018) 0.007
Scale 1.762 (1.625 to 1.899) ,0.001
Shape 0.408 (0.314 to 0.502) ,0.001
athe relative interaction terms containing this parameter were also excluded.
IHD= ischaemic heart disease; GGT = gamma-glutamyltransferase; ALP = alkaline phosphatase; IDI = Integrated Discrimination Improvement.
Notes: The baseline parameters are listed in decreasing order of IDI. A negative coefficient for a parameter indicates an increasing effect on mortality risk, whilst a
positive coefficient indicates a decreasing effect on mortality risk.
doi:10.1371/journal.pone.0050965.t003
Figure 2. Number of predicted and observed mortality events
one year after initial LFTs.
doi:10.1371/journal.pone.0050965.g002
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web-based tool to see the impact of ALFI on clinical decision
making, further investigations, patient outcomes, and costs to the
health service. The majority of deaths were from previously
undiagnosed cancer and cardiac disease which may warrant
further investigation.
ALFI will give an individualised prognosis based on the patient’s
characteristics, LFTs, comorbidity history and statin use. The
resulting probability estimate combined with other clinical
information (not available as potential predictors for the model)
at the GP’s disposal might facilitate their decision-making with
regards to further investigations, referral or watchful waiting. With
its extremely high NPVs, ALFI has an excellent ability to
accurately assign a low probability of short term mortality. For
example, if we take 0.61% as our predicted probability cut-off, the
model can accurately identify those patients with a very low
probability of poor prognosis and the GP can confidently use this
with any other contextual information not in the model e.g. body
mass index, smoking status, alcohol intake, to inform their decision
making. Using the model alone, with such a cut-off the GP would
under investigate 83/47989 (0.2%) patients but correctly rule-out
one-year mortality in 47906/47989 (99.8%) patients. Further-
more, at this cut-off the sensitivity is very high since ALFI detected
97% of all actual deaths within the year. However, the PPV was
low meaning that 94.3% of patients detected over the cut-off
would be over-investigated. However patient outcomes beyond
one year may be improved by investigation. The use of clinical
parameters without LFTs in the model had high enough sensitivity
to give very similar NPVs given the low overall risk of mortality.
Table 4. Performance measures for different cut-offs of predicted probability of mortality for the final model.
Cut-off for predicted
probability,%
Number (%) of patients over
cut-off (out of 95,977) Sensitivity, % Specificity, % PPV, % NPV, %
$0.611a 47989 (50) 97.0 51.4 5.69 99.8
$2.78b 23996 (25) 84.8 76.8 9.94 99.4
$5 15068 (15.70) 72.9 86.0 13.6 99.1
$7.75c 9598 (10) 60.7 91.5 17.8 98.7
$10 7058 (7.35) 52.8 94.0 21.0 98.5
$13.2d 4799 (5) 43.6 96.2 25.6 98.3
$20 2546 (2.65) 30.7 98.2 33.9 97.9
$30 1173 (1.22) 18.9 99.3 45.3 97.6
$32.9e 960 (1) 16.5 99.5 48.4 97.5
$40 620 (0.65) 12.2 99.7 55.1 97.4
$50 323 (0.34) 7.47 99.9 64.9 97.3
$60 173 (0.18) 4.55 100 73.6 97.2
$70 96 (0.10) 2.79 100 81.0 97.1
Cut-offs at: a50th; b75th; c90th; d95th; e99th percentile.
PPV =positive predictive value; NPV= negative predictive value.
doi:10.1371/journal.pone.0050965.t004
Table 5. Performance measures for different cut-offs of predicted probability of mortality for the final model excluding all LFT
terms.
Cut-off for predicted
probability,%
Number (%) of patients over cut-
off (out of 95,977) Sensitivity, % Specificity, % PPV, % NPV, %
$0.953a 47990 (50) 95.4 51.4 5.77 99.7
$3.84b 23994 (25) 78.1 76.7 9.45 99.1
$5 19235 (20.04) 71.1 81.6 10.7 98.9
$8.98c 9598 (10) 48.6 91.2 14.7 98.3
$10 8031 (8.37) 43.8 92.8 15.6 98.1
$13.0d 4798 (5) 30.7 95.8 18.6 97.8
$20 1317 (1.37) 12.5 99.0 25.6 97.3
$21.8e 959 (1) 9.28 99.3 28.0 97.2
$30 257 (0.27) 4.22 99.9 34.5 97.0
$40 54 (0.06) 1.55 100.0 41.2 97.0
$50 8 (0.01) 0.289 100.0 49.4 97.0
$60 3 (0.003) 0.123 100.0 51.1 97.0
Cut-offs at: a50th; b75th; c90th; d95th; e99th percentile.
PPV =positive predictive value; NPV= negative predictive value.
doi:10.1371/journal.pone.0050965.t005
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However, the PPV increased at a lesser rate and sensitivity
reduced at a greater rate as the cut-offs increased meaning that
LFTs contributed more to the proportion of true positives than to
true negatives. For example, for a predicted probability cut-off at
the 75th percentile (3.84% for the model without LFTs and 2.78%
for the model with LFTs) the sensitivity improved from 78.1%
without LFTs to 84.8% with LFTs. Even with LFTs included the
PPV never gets as high as the NPV and as it increases the
sensitivity decreases dramatically. For example, if we used the
model to refer those with a very high mortality risk of greater than
60%, the GP would over-investigate 26.4% patients but correctly
investigate 73.6% patients. However, at this cut-off the sensitivity
is extremely poor meaning that ALFI would fail to detect 95.4% of
those who did die within the year. With such small numbers at
high cut-offs and with poor sensitivity, it is clear that ALFI
performs best at low cut-offs of predicted risk but at the expense of
low PPV.
One prediction model involving liver disease is the Model for
End-Stage Liver Disease (MELD) [31]. This model was originally
developed to predict short-term survival (3 months and one year)
of patients with cirrhosis who were about to go through the
transjugular intrahepatic portosystemic shunt procedure. MELD
consisted of a range of parameters including serum bilirubin,
creatinine levels, International Normalised Ratio for prothrombin
time, and aetiology of liver disease. In 2001, the model was
validated for a wider group of patients, with a range of liver disease
severity and aetiology, who were awaiting liver transplant [32].
MELD was then developed as a replacement for the use of waiting
time as a measure of the organ allocation priority.
Similarly, the ALFI model could be used to prioritise referrals to
secondary care. However, it would not tell the user who to refer to
as this would require additional contextual information and
clinical judgement. ALFI’s main use could be to identify those who
have a very low probability of death and do not need further
investigation for severe life threatening conditions. It would not,
however, detect those who have important underlying conditions
that might reduce survival in the longer term or non fatal
conditions than can impair quality of life and still need a diagnosis
and appropriate treatment.
Strengths and weaknesses
This is the first successfully derived and externally validated
population risk prediction model for one year all-cause mortality
in primary care patients with LFTs using a large population
dataset. The ability of the model to discriminate between patients
at high and low risk was excellent (c = 0.82) and the calibration
curve showed reasonable accuracy of the probability estimates
from the prediction model across the range of values of predicted
risk. The discrimination of ALFI when applied to the external
cohort was also excellent (c = 0.86). In comparison, the Framing-
ham equation c-statistic ranged from 0.63 to 0.83 for its external
validation on six different cohorts [30], and a model predicting risk
of emergency admissions reported a discrimination of 0.79 for its
validation group [13].
ALFI was derived from unselected ‘‘real-world’’ observations in
a geographically defined population: an approach being encour-
aged by the National Institutes of Health [33]. Strengths of the
Figure 3. Survival curves for males (a) and females (b) by history of cancer and stroke status during the first year of follow-up.
doi:10.1371/journal.pone.0050965.g003
Figure 4. Predicted probability of surviving during the year for
the average risk patient and two example cases. Example 1
patient: 55 year old male, albumin= 28 g/L, ALP = 137 U/L, biliru-
bin = 9 mmol/L, GGT= 86 U/L and transaminase = 41 U/L. Example 2
patient: 54 year old male, history of cancer, albumin = 38 g/L,
ALP = 1133 U/L, bilirubin = 8 mmol/L, GGT= 114 U/L and transamina-
se = 25 U/L. Probability of surviving up to one year for each of these
patients was 0.99, 0.80, and 0.21 respectively.
doi:10.1371/journal.pone.0050965.g004
Predicting Mortality following Liver Function Tests
PLOS ONE | www.plosone.org 8 December 2012 | Volume 7 | Issue 12 | e50965
data used in this study were the large study population size, the
high quality of established national databases, and the determin-
istic linkage using the CHI number. A weakness of electronic
databases was the lack of some potentially useful predictors of
mortality, such as alcohol intake, smoking, presence or severity of
heart failure, and body mass index. Whilst we have no specific
data on the clinical indications for requesting LFTs, we were able
to identify patients with a history of major co-morbidities since
1980, including cancer, diabetes, and IHD using SMR hospital
admission records and population registers, and patients who were
prescribed statins, NSAIDs, and antibiotics in the three months
before their initial LFTs. Although patients with a diagnosed
history of liver disease were excluded from the analysis, it is
possible that patients with very early asymptomatic undiagnosed
liver disease were included. However, we have no way of
estimating this from the data. In fact, one could argue that
clinical indications, asymptomatic undiagnosed liver disease,
alcohol dependency and obesity may correlate highly with LFTs,
since the latter are markers for such [3,34,35], resulting in
multicollinearity and their exclusion during the model building
process. As for all statistical models, residual confounding may be
present due to not adjusting for unavailable factors such as drugs.
For example, metformin which is used to treat Type 2 diabetes has
been shown to prevent cancers in the digestive organs [36,37].
With the recent advancement of primary care data extraction
systems [38], the potential for incorporating further databases e.g.
genetic [39], and the improvement in data recording, we will have
the ability in the future to include further potential prognostic
factors to update ALFI.
LFTs are non-specific markers of illness i.e. either disease
processes in the liver, local involvement from disorders of other
organs, or as a marker of systemic disease. The inflammatory or
infective liver diseases tend to produce abnormality of the
transaminases and may produce mortality rises in the long term
(decades) but the effects of other organ disorders (e.g. aggressive
cancers or heart disease) are more likely to be manifest in the short
term, so a one-year follow-up period was chosen for this study.
The algorithm is not a diagnostic one but an aid to clinical
decision making and all-cause mortality was deemed the most
appropriate to ‘catch all’ patients with very poor or very good
prognosis. Clearly, a model for mortality over a longer follow-up
period would have a poorer predictive ability following one set of
LFTs since other events would intervene. In contradistinction the
use of LFTs as a predictor of outcome in chronic liver disease
would need a much longer follow-up period as the natural history
of most primary liver diseases is decades. The model including
LFTs had better discriminatory ability and higher PPV than the
model without. Furthermore, albumin and ALP explained the
second and third most variation of all the predictors in the model
proving that LFTs are valuable prognostic factors for short term
mortality.
GGT
GGT was missing for a large proportion of patients in the
derivation cohort but less so in the validation cohort. However the
appropriate guidelines for handling this problem were followed
[40]. The demographics of the patients with complete data (i.e.
males, illicit drug users, alcohol dependents, and patients living in
deprived areas) suggested that general practitioners requested
GGT where they suspected that there may be a chance of
substance abuse [41]. Therefore it was assumed that the missing
data depended on variables in the observed data - the missing at
random assumption which is required for multiple imputation
[25]. Although the percentage of patients untested for GGT was
89.1%, with such a large cohort this still meant that data from
10484 patients were used to impute GGT. Relative efficiency is
the efficiency of an estimate obtained from m imputations relative
to one obtained from an infinite number of imputations [25]. The
value used is arbitrary but obviously the closer to 100% the better.
The dataset was imputed 30 times to allow a more precise
parameter estimate for GGT which gave a relative efficiency value
of 97.1% for 90% missing data. When the final model was fitted to
a complete dataset excluding GGT the parameter estimates were
reasonably similar to those from the model fitted to the imputed
dataset. This is reassuring as it suggests that the inclusion of a
highly imputed GGT does not cause the other predictors
parameter estimates to vary by much, thus ruling out biased
imputations of GGT (Appendix S2). In Tayside, the laboratories
do not routinely include GGT with the other four LFT results
unless specifically requested by the general practitioner. However,
in the external validation cohort GGT was much more complete
(64.1%) meaning that other labs do measure GGT routinely.
Therefore we perceive the inclusion of GGT in the model as an
advantage so that GPs from these regions can include this test in
the model. We have shown that GGT had the seventh highest IDI
value of all the predictors, suggesting that its use should be re-
evaluated in those regions that do not test for it consistently.
Cancer
Out of 95977 patients from the derivation cohort, 2613 died
(2.7%) within one year. Almost 40% of the 2613 deaths were
caused by cancer. A Korean study prospectively followed up
142055 men and women who had a transaminase test for a
maximum period of 8 years and they also found that out of 3786
deaths, 46.2% were from cancer [6]. A history of cancer was also
highly predictive of mortality within one year. Over three-quarters
of those who died from cancer did not have a history of the
disease. Further research could involve determining the predictive
ability of LFTs for outcomes related to cancer in those without
known cancer diagnosis.
External validation
External validation of prediction models is extremely important
in order to support their application and transportability to
different geographical or temporal populations. Since our external
cohort came from 19 primary care practices across nine different
regions of Scotland during a different time period than the
population used to develop the model, we have shown that ALFI
predicts well with regards to both aspects. The fact that the
external cohort had patients with greater rates of deprivation and
comorbidity than the derivation cohort shows that the model is
robust to changes in baseline characteristics. The median LFT
values for both cohorts were very similar, as were the proportions
of patients who died within one-year. The next step is to convert
ALFI into a web-based decision aid to assess its impact on GP
management of these patients. Using the sensitivity and PPV
results, suggested management plans can be determined for
different risk cut-offs. A feasibility study of its implementation,
focused on general practitioner acceptability and impact on
decision making and costs might then usefully follow.
Conclusions
This study has developed and externally validated a novel risk
prediction model for one-year mortality in patients, with no
clinically obvious liver disease, having their LFTs taken in primary
care. All five LFTs were predictive of mortality and improved the
discriminatory ability, sensitivity and PPV of the model. ALFI
performs best at lower cut-offs of predicted probabilities of
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mortality with excellent sensitivity and NPV and good specificity.
However, low PPV may mean over-investigation of some patients.
However, the addition of LFTs did not improve NPV for short
term mortality in these types of patient and only modestly
improved the PPV. Therefore the clinical utility of ALFI as a
decision tool in primary care needs to be established in terms of
further testing, patient outcomes and health service costs. The
utility of liver function testing per se needs to be further examined
using other outcomes such as impact on the detection of
modifiable diseases such as chronic liver disease.
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